A Randomized, Double-Blind, Multicenter, Phase 2 Trial of Exemestane (Aromasin) plus Dasatinib versus Exemestane plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI)

Patients with metastatic breast cancer will be randomized to receive aromasin alone or in combination with dasatinib.